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Photoreceptor degenerationA subretinal visual implant (Alpha IMS, Retina Implant AG, Reutlingen, Germany) was implanted in 29
blind participants with outer retinal degeneration in an international multicenter clinical trial. Primary
efﬁcacy endpoints of the study protocol were a signiﬁcant improvement of activities of daily living
and mobility to be assessed by activities of daily living tasks, recognition tasks, mobility, or a combination
thereof. Secondary efﬁcacy endpoints were a signiﬁcant improvement of visual acuity/light perception
and/or object recognition (clinicaltrials.gov, NCT01024803).
During up to 12 months observation time twenty-one participants (72%) reached the primary end-
points, of which thirteen participants (45%) reported restoration of visual function which they use in daily
life. Additionally, detection, localization, and identiﬁcation of objects were signiﬁcantly better with the
implant power switched on in the ﬁrst 3 months.
Twenty-ﬁve participants (86%) reached the secondary endpoints. Measurable grating acuity was up to
3.3 cycles per degree, visual acuities using standardized Landolt C-rings were 20/2000, 20/2000, 20/606
and 20/546. Maximal correct motion perception ranged from 3 to 35 degrees per second. These results
show that subretinal implants can restore very-low-vision or low vision in blind (light perception or less)
patients with end-stage hereditary retinal degenerations.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Hereditary retinal degenerations (e.g. retinitis pigmentosa, RP)
are characterised by progressive loss of rod and/or cone function
over years or decades, frequently leading to blindness in middleage. Several therapeutic approaches are under development for
hereditary degeneration of the outer retina, including
gene-therapy (Bainbridge et al., 2008; Busskamp et al., 2012;
Maguire et al., 2009), electrostimulation (Schatz et al., 2011) and
microelectronic visual implants (Humayun et al., 2012; Stingl
et al., 2013b; Stingl & Zrenner, 2013b; Zrenner et al., 2011).
Many of the attempts are in preclinical stage; some are in clin-
ical trials. Their applicability depends on various factors: early
stages of photoreceptor degenerations may beneﬁt from gene ther-
apy or neuroprotection. Gene replacement therapy has been suc-
cessfully applied in several gene mutations causing hereditary
Fig. 1. Retina Implant Alpha IMS: detail on the device. The Retina Implant Alpha
IMS consists of the vision chip (multiphotodiodes array) on a polyimide foil (both
placed subretinally), a power supply cable connecting the microchip with the
receiver coil in a ceramic housing and the reference electrode placed subdermally at
the temple and retroauricular region.
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et al., 2009), where not only rescue of the remaining vision, but
also an improvement in several patients in a 3-years follow-up
has been reported (Testa et al., 2013). Neuroprotective effects via
release of endogenous growth factors have been demonstrated
by transcorneal electrostimulation (Schatz et al., 2011) or intraoc-
ularly applied growth factors (Sieving et al., 2006), however their
degree of efﬁcacy has not yet been ﬁnally evaluated. In late stages
of hereditary retinal degenerations rods and cones are almost com-
pletely lost. Treatment options considered in such cases are ‘‘opto-
genetics’’ where inner retina cells are made light sensitive by
means of channel rhodopsins, or stem cells, all applied so far not
yet in clinical studies. At present only electronic implants are avail-
able for patients blind from hereditary retinal degenerations.
Several types of electronic retinal implants have either been
approved as commercial products such as Argus II, (Second Sight,
Sylmar, CA, see Humayun et al., 2012) and Alpha IMS (Retina
Implant AG, Reutlingen, Germany, see Stingl et al., 2013b) or are
under development (Ayton et al., 2014; Guenther, Lovell, &
Suaning, 2012; Luo & da Cruz, 2014; Menzel-Severing et al.,
2012; Stingl & Zrenner, 2013; Zrenner, 2013) for the treatment of
hereditary retinal degenerations. Their aim is to restore some
vision in end-stage disease for patients who are completely blind
or who have light perception without light localization. All of these
implants consist of a light-capturing unit (an external camera or an
intraocular photodiode array) and an electrode array for stimula-
tion of retinal neurons, mostly those in the inner retina. By electri-
cally stimulating the remaining neurons, the implants initiate a
visual percept, replacing to some extent the lost photoreceptor
function with artiﬁcial vision.
The two types of implants available commercially, the subreti-
nal implant Alpha IMS (Retina Implant AG; Reutlingen, Germany)
and the epiretinal implant Argus II (Second Sight, Sylmar, CA) differ
in their function in two major aspects: the epiretinal implant has
an external head mounted camera and stimulates the ganglion
cells of the retina, the third visual pathway neuron whose axons
build the optic nerve. The number of stimulation electrodes
reaches currently up to 60 and the signal is processed in an exter-
nal computer and decoded via an epibulbar device that drives the
60 electrodes via transocular wires for an optimal stimulation of
the ganglion cells at the retinal output. In contrast, the subretinal
implant has a light sensitive 1500 photodiode-array positioned in
the layer of the degenerated photoreceptors (subretinally) and
stimulates the bipolar cells layer at the retinal input (the second
visual pathway neuron, which is connected to the photoreceptors
in a healthy eye) and thereby uses the processing power of the
neuronal network of the inner retina. The photodiodes are coupled
via 1500 ampliﬁers directly to the stimulation electrodes in an
array of independent 1500 ‘‘pixels’’.
A consortium led by the University of Tübingen has been devel-
oping various types of active subretinal visual implants since the
1990s (Zrenner, 2002; Zrenner et al., 1999). After preclinical bio-
compatibility, safety, and biostability tests (Gekeler et al., 2007;
Guenther et al., 1999; Kohler et al., 2001; Schwahn et al., 2001),
a ﬁrst wire-bound version of the subretinal implant with 1500 pix-
els was tested in a pilot study in 11 blind volunteers, where a
retroauricular transdermal cable connected the visual implant
with an external battery supply. Surprising functional outcomes
in three of the subjects, allowing for recognition of unknown
objects and even reading large letters, including the detection of
spelling errors, were published (Stingl et al., 2013c; Zrenner
et al., 2011). Subsequently, a version with wireless transmission
of power and signals (transdermally via coils in the retroauricular
region, see Figs. 1 and 2), the subretinal implant Alpha IMS of
Retina Implant AG, Reutlingen, Germany was implanted in further
29 eyes of 29 blind participants with degeneration of the outerretina in an ongoing clinical trial that consists of module 1 (a single
centre study in Tübingen) and module 2 (a multicentre trial at
authors’ sites). Primary efﬁcacy endpoints were a signiﬁcant
improvement of activities of daily living and mobility shown via
activities of daily living tasks, recognition tasks, mobility, or a com-
bination thereof. Secondary efﬁcacy endpoints were a signiﬁcant
improvement of visual acuity/light perception and/or object recog-
nition (clinicaltrials.gov, NCT01024803). Results from the nine par-
ticipants in module 1 have been published (Stingl et al., 2012,
2013b,c). This manuscript describes the results obtained in the
multicentre trial, with a combined analysis of the original nine
module-1-participants and the additional 20 participants recruited
in module 2.
2. Material and methods
2.1. Participants
Twenty-nine participants (13 females, 16 males) with a mean
age (±standard deviation) of 53.8 ± 8.2 years (range 35–71 years)
were enrolled in the clinical trial (www.clinicaltrials.gov,
NCT01024803) and received the implant in one eye. Visual func-
tion prior to implantation was light perception without projection
(20 participants) or no light perception (9 participants) as tested by
the ophthalmologist using the standard ﬂashlight test manually by
direct illumination of the eye from 5 directions. The loss of vision
was caused by hereditary degenerations of the photoreceptors
(25 participants had retinitis pigmentosa, 4 had cone-rod dystro-
phy). None of the participants had other eye diseases that might
have affected the visual pathway. Written informed consent was
obtained from all participants and the trial was conducted in accor-
dance with the declaration of Helsinki. Research ethics committee
approval was obtained for all 7 sites.
2.2. Subretinal Implant Alpha IMS
The Retina Implant Alpha IMS (Fig. 1) consists of a subretinal
microphotodiode-array (MPDA, the ‘‘microchip’’) on a polyimide
foil and a cable for power supply and signal control, ending in a
receiver coil, housed together with electronic circuits in a small
subdermal box behind the ear, similar to technology used in
cochlear implants (Fig. 2). A separate short cable connects the
return electrode to the subdermal box. The MPDA consists of
1500 independent photodiode-ampliﬁer-electrode units, each of
which transforms the local luminance information into an electri-
cal current that is ampliﬁed for the stimulation of the adjacent
Fig. 2. Retina Implant Alpha IMS: clinical setting. (A) Illustration of the placement of the receiver coil and the power supply cable in an X-ray image. (B) Image of the Retina
Implant Alpha IMS on the eye fundus. (C) Handling of the hand held unit: for activation of the visual chip the transmitter coil has to be put on top of the receiver coil and is
kept in place magnetically behind the ear. The coils provide a wireless inductive transfer of energy and control signals. The participant can switch on or off the device on the
hand held unit, as well as adjust contrast sensitivity and brightness manually via two knobs (adapted from Stingl et al., 2013b).
K. Stingl et al. / Vision Research 111 (2015) 149–160 151bipolar cells (Eickenscheidt et al., 2012; Stett et al., 2000) via a
50  50 lm titanium nitride electrode. Thus, a point-by-point elec-
trical image of the luminance information is forwarded to bipolar
cells and processed in the inner retina and the afferent visual path-
way. Each electrode of the chip typically releases 1 ms pulses in a
deﬁned frequency, usually 5 Hz, creating a slightly ﬂickering per-
ception consisting of up to 9 grey levels (Zrenner et al., 2011). As
each photodiode-electrode unit theoretically works independently
from the neighbouring ones (although in vitro experiments point
out that there might be interferences of the electric ﬁelds of each
electrode), the image reported by the patients reminds of a blurred
screen of a black-and white television set allowing for shape per-
ception up to a theoretical two-point resolution of 0.25 of visual
angle.
An external battery-driven power supply equipped with a
transmitter coil permits an inductive transfer of energy and control
signals (Fig. 2). A special feature of the subretinal implant is that
the light-to-voltage conversion of the luminance information fall-
ing onto the retina, used for electric stimulation of the retinal bipo-
lar cells (Eickenscheidt et al., 2012; Stett et al., 2000), maintains
retinotopy in the moving eye. On the external device Retina
Implant Alpha IMS has manual adjustment of contrast and bright-
ness for deﬁning the transfer characteristic output curve allowing
optimal contrast vision in different luminance conditions. Further
technical details have been published earlier (Stingl et al., 2013b;
Zrenner et al., 2011, including electronic data supplements).2.3. Surgical implantation
The subretinal implant was surgically implanted into one eye,
under general anesthesia. As depicted in Fig. 2, the polyimide foil
that carries the microchip leads subretinally toward the retinal
periphery, where it exits the intraocular space through the choroid
and sclera. By means of a sealed ceramic connector piece, sutured
onto the sclera, the gold wires printed on the foil connect to the
round cable that makes a loop within the orbital space (to allow
for free eye movement) before it leads to the retroauricular elec-
tronic box. Further details on surgical technique have been pub-
lished (Besch et al., 2008; Sachs et al., 2010).
2.4. Study procedures
Primary efﬁcacy endpoints of the study protocol were a signif-
icant improvement of activities of daily living and mobility to be
assessed by activities of daily living tasks, recognition tasks, mobil-
ity, or a combination thereof. Secondary efﬁcacy endpoints were a
signiﬁcant improvement of visual acuity/light perception and/or
object recognition (clinicaltrials.gov, NCT01024803).
Protocol-mandated follow-up extended to 1 year, and included
serial retinal imaging with multiple tests of visual function, and
adverse event reporting (Stingl et al., 2013a). It was not possible
to simulate sham surgery, hence participants served as their own
internal controls, comparing the visual function with the implant
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was not indicated to the patient. Additionally, in most of the
patients, tests were performed using light levels that were not
visible via the remaining photoreceptors in the eye, if those pho-
toreceptors had retained light perception. The following tests
(Stingl et al., 2013a; Zrenner et al., 2011) were repeated in up to
7 follow-up visits during the year of observation.
2.4.1. Basic visual functions (‘‘screen tasks’’)
Light threshold perception, light source localization, and motion
detection of dot patterns were tested on a 60 cm distant screen as
2- or 4-alternatives forced-choice (AFC) tests (Basic Light and
Motion – BaLM test) in 8 or 12 trials each. The methodology of
the BaLM test that is now mentioned by the FDA as one of the pos-
sible tests for electronic implants has been described in detail
(Bach et al., 2010, Food and Drug Administration. Investigational
Device Exemption Guidance for Retinal Prostheses, 2013) and
was used here to measure the secondary endpoints of the study.
The participant was asked whether he/she has seen a ﬂash of
light (2AFC, light threshold perception), to localize the illuminated
part of the screen (4AFC, light source localization) and to deter-
mine the movement direction of a dot pattern (4AFC, motion
detection). The ﬁrst speed tested was 3.3 degrees per second
(dps) as the default value set in BaLM. If the participant passed
the motion detection, the speed was increased to 5 dps, 7 dps or
higher values according to the examiners’ consideration. The par-
ticipant responded via a keyboard or verbally. Due to simplicity
of the screen tasks there were no training procedures.
At least 75% (in 2-AFC) or 62.5% (in 4-AFC) correct responses
were required to pass the test (deﬁned by the inﬂection point of
the sigmoid psychometric curve). Feedback was given after com-
pletion of each test.
2.4.2. Spatial resolution
Grating acuity and visual acuity (VA) with standardized Landolt
C-rings in contrast reversal (white ring on black background), the
secondary endpoints of the study, were tested on a 60 cm distant
screen as 2- or 4-alternatives forced-choice tests in 8 or 12 trials
per resolution level. The participant was asked to tell the orienta-
tion of the grating and the direction of the C-ring gap respectively.
The participants responded via a keyboard or verbally without
time limitations. In most of the patients a short training was per-
formed prior to the very ﬁrst test by showing and explaining the
vertical grating pattern and/or the C-Ring in the middle of the
screen. At least 75% (in 2-AFC) or 62.5% (in 4-AFC) correct
responses were required to pass the test. Feedback was given after
completion of each test.
2.4.3. Activities of daily living and recognition tasks
Recognition tasks and activities of daily living (ADL) tasks, the
primary endpoints of the study, were performed on a black table
using white objects. A short training procedure preceded the tests,
except ‘‘grey scales’’, to make the volunteer acquainted with the
objects visually and by touch. After completion of each test trial,
feedback about correctness of the responses was given. The lumi-
nance of the white objects on the table was usually around 200–
600 cd/m2, that of the black table cloth usually below 30 cd/m2.
2.4.3.1. Geometric shapes. Four objects of about 5 visual angle each
were placed in front of the participant, who was not informed
about the number of the objects. The participant had to report
how many objects were present, point to their position, and
describe what they were (shape description and localization) with
a timeout of 4 min. Correct responses were documented as scores
(from 0 to 4 for each of the three questions; for example, if the
patient reported ‘I can see three shapes: a circle (points towardthe crescent), a triangle (points toward the triangle) and a square
(points toward the square)’, the documented scores are identiﬁca-
tion 3, recognition 2 and localization 3).
2.4.3.2. Table setup. Four dining objects (such as cups and cutlery)
were placed around a white large plate in front of the participant,
who was not informed about the number of the objects. The partic-
ipant had to report how many objects were present around the
plate, localize them, and identify them (shape description) with a
timeout of 4 min. Correct responses were documented as scores
(from 0 to 4 for each of the three questions).
2.4.3.3. Clock task. White clock hands were placed at angles of 0,
90 or 180 to each other indicating a clock time. This therefore
presented a 16-alternative forced choice test; a response rate
above 53% was taken as a pass. The participant was asked to ‘‘tell
the time’’ with a timeout of 2 min. During each test (one per study
visit) the participant had to read a randomly set clock, 12 times.
2.4.3.4. Letters. Participants were asked to read white letters on a
black background (26-alternative forced choice test; a response
rate above 52% was taken as a pass). The letter size subtended a
visual angle of up to 10. Timeout of each letter reading was 2 min.
2.4.3.5. Grey levels. The aim of this test was to deﬁne the number of
grey levels which can be distinguished within the luminance trans-
fer function. An intermediate grey color was presented on one half
of a screen with one of six different levels of grey on the other half
of the screen: three brighter levels (Michelson contrast in compar-
ison to the intermediate grey 0.29, 0.52 and 0.63) and three darker
levels (Michelson contrast in comparison to the intermediate grey
0.96, 0.56 and 0.33). Each of the six combinations was presented
three times in random order. Participants were asked which side
of the monitor was brighter. Combinations of different grey levels
which were distinguished correctly at least twice were docu-
mented as recognized. Number of recognized grey scales was the
endpoint result of the test. A full screen at the intermediate grey
level served as control. There was no timeout for the responses.
The light levels for the screen tests were usually adapted indi-
vidually to interfere as little as possible with eventually present
remaining light perception and light sensitivity of the MPDA was
set such that the dark areas of the screen evoked minimum
currents and the light areas evoked maximum currents; the
bright light level of the screen tasks was usually between 100
and 2500 cd/m2 and of the black areas approx. 0.1–50 cd/m2,
respectively.
2.4.3.6. Patients’ reports. Additionally, patients used the implant at
their homes and in daily living and reported subjectively their
visual experiences. These reports were documented to analyze
improvements in orientation and mobility in daily lives of the par-
ticipants (one of the primary endpoints of the study).3. Results
Twenty-one participants (72%) reached the primary efﬁcacy
endpoints as set in the study protocol (‘‘signiﬁcant improvement
of activities of daily living andmobility shown via activities of daily
living tasks, recognition tasks, mobility, or a combination thereof’’).
Twenty-ﬁve participants (86%) reached the secondary endpoints
(‘‘signiﬁcant improvement of visual acuity/light perception and/or
object recognition’’). The following paragraphs give details on the
performance for the particular tests. For summary of results with
the implant switched on for each patient see Table 1.
Table 1
Table shows the best achieved results for each participant in the function tests with the implant power on. In AFC tests (Light perception, Light source localization, clock task,
reading letters) ‘‘ + ’’ indicates the participant passed the test, ‘‘’’ indicates he/she failed. Motion perception results show the highest speed where the participant was able to
distinguish the motion direction correctly (‘‘dps’’ means degrees per second). Grating acuity results is documented in cycles per degree (‘‘cpd’’), the visual acuity as tested by
Landolt C-rings in the Snellen fraction. For grey levels the number of correctly distinguished shades of grey is shown. For the categorization of daily life experiences please see the
text.
Light Location Motion [dps] Grating acuity [cpd] Landolt C VA Grey levels Clock Letters Daily life experiences
TU-01  na na na na na  na None
TU-02 + +    na + + Useful
TU-05 + + 3 0,33  na   Useful
TU-06 +    na na  na Little
TU-07 + + na 0,3 20/2000 na   Useful
TU-08 + + 7 0,3  3 na + Useful
TU-09 + + 35 3,3 20/546 na + + Useful
TU-10 + + 5 0,5  4 na  Little
TU-12 + + 5 1  3 + + Little
TU-14 + + na  na 5 na na None
TU-15 + +  1 na 1  na Little
BU-01         None
BU-02 +    na 4   Useful
DD-01 + +   na na na na Useful
DD-03 +  na na na    None
LO-01 +  3,3 0,33 na 2  na Useful
LO-07 + +  0,1 na na  + Useful
LO-08 + +   na na na na None
LO-16 + +   na 2 na na Little
OX-01 +     3   Little
OX-02 + +  0,33 na 5   Useful
OX-03 +   0,33 na 4   Useful
OX-04 + +  1  4   Useful
OX-05 + +  0,33  4 +  Little
OX-06 + +  1 20/2000 6 +  Useful
SI-01    na na na na na None
SI-02 +        Little
HK-01 +   na 20/606 6   None
HK-02        na None
% passed 86% 59% 21% 48% 14% 52% 17% 14% 45%
‘‘na’’ means not assessable; the visual function of the patient did not allow to perform the test.
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3.1.1. Activities of daily living and recognition tasks
3.1.1.1. ADL: geometric shapes. Scores with implants on and off
were compared pair-wise with a non-parametric (Wilcoxon) test.
Detection, localization, and recognition of geometric shapes in a
good contrast was signiﬁcantly better with the implant power on
compared to off during the ﬁrst three months (Fig. 3). From the
month 6 visits and beyond, the statistical signiﬁcance decreased
(p > 0.05) for most of the on–off comparisons, (Fig. 3). This might
be due to fewer data, as well as to a slight increase in the perfor-
mance with the implant power off, as discussed below.
3.1.1.2. ADL: table setup. Scores with the implant on and off were
compared pair-wise using all available data and the Wilcoxon test.
Detection, localization, and recognition of table objects in a good
contrast was signiﬁcantly better with the implant on compared
to off during the ﬁrst three months (Fig. 3). From the month 6 visits
and beyond, the statistical signiﬁcance decreased (p > 0.05) for
most of the on–off comparisons (Fig. 3). This might also be due
to fewer data and a slight increase in the performance with the
implant power off.
3.1.1.3. Clock task. Using the non-parametric (Wilcoxon) test the
performance over all subjects was not statistically signiﬁcantly
better with implant on vs. off for the clock task (Fig. 4A). Five par-
ticipants passed the test at least once during the trial visits and
could read the clock hands and tell the time (Table 1). One partic-
ipant passed the clock task once with the implant turned off.
3.1.1.4. Letters. Using the non-parametric (Wilcoxon) test the per-
formance over all subjects was not statistically signiﬁcantly betterwith implant on vs. off for the clock task (Fig. 4B). Four participants
passed the test at least once during the trial visits and could read
letters (Table 1). Additionally, one participant (TU-12) passed the
test with the implant turned on as well as off at the end of the
study (month 9), probably using a peripheral residual ﬁeld with
widened pupils, whereas the patient could not read letters at the
time of screening; this positive development may be due to bene-
ﬁcial effects described for electrical stimulation treatment (see
Section 4).
3.1.1.5. Grey levels. Using the non-parametric (Wilcoxon) test the
performance over all subjects was signiﬁcantly better (p < 0.05)
with implant on vs. off for grey levels recognition in months 1, 2
and 12 (Fig. 4C).
Fifteen participants (52%) were able to recognize at least one
grey level, ranging up to six (only six levels were tested in the pre-
sent study), compared to an intermediate grey level. The number of
grey levels correctly distinguished is illustrated in Table 1. Eight
participants (28%) recognized up to three grey levels with the
implant off.
3.1.2. Daily life experiences
Participants used the visual implant during their daily life, at
home, outdoors, or at work, usually up to 2–3 h daily. The type
of vision experienced was described as a blurred image, consisting
of shapes of different grey levels, slightly ﬂickering (due to the
working frequency of the implant, typically 5 Hz), in a
square-shaped visual ﬁeld of up to 15 diagonally (Stingl et al.,
2012, 2013b). Several participants spontaneously reported a slight
improvement of the remaining light perception with the implant
off during the course of the study; however, none of them could
see objects without the implant power being switched on.
Fig. 3. ADL tasks. ADL tasks for shapes and table setups (see Section 2.4.3). Nonparametric testing showed signiﬁcant differences between the scores achieved with the
implant power switched on vs. off for all test questions in the ﬁrst three months (see Sections 3.1.1.1 and 3.1.1.2). ‘‘n’’ indicates number of participants with available data for
the particular visit; * and ** indicate statistic signiﬁcances of p < 0.05 and p < 0.001 resp. The value for ‘‘table what’’ score at month 12 is zero.
154 K. Stingl et al. / Vision Research 111 (2015) 149–160Eight participants (28%, including the four who did not have
any light perception via the implant) did not beneﬁt in daily life.
A further eight participants (28%) could localize objects with a
good contrast in their daily life, but could not recognize shapes
or details (Fig. 5). Thirteen participants (45%) reported useful
new daily life experiences with the implant, being able to see
shapes and/or details of objects in grey scales (Table 1, Fig. 5).
Some of their visual experiences match the criteria of improving
independence and social connectedness as proposed recently for
the endpoints of visual prostheses (see The Lasker/IRRF
Initiative for Innovation in Vision Science, 2014a, chap. 3). The fol-
lowing visual experiences were described with the implant power
on (examples).3.1.2.1. Facial and other personal features. Participants reported see-
ing the shape of another person’s head, mouth, glasses, a baby in a
white dress, scarf around the neck, and other features.3.1.2.2. Buildings. For example, house outlines, windows, town-hall
silhouette, and curtain stripes.
3.1.2.3. Outdoors. Street lamps at night showing the direction of the
street, pavement lines, arches of a viaduct, landmarks, and others.
3.1.2.4. Vehicles. Car lights moving at night, car reﬂexions, recog-
nizing different types of buses.
3.1.2.5. Nature. Sunﬂower stalk, river on the horizon, dog-tail wag-
ging, garden table, moon, and others.
3.1.2.6. Own body. Hand, head silhouette in the mirror, striped
jacket in the mirror.
3.1.2.7. Indoors. Such as picture frame on the wall, ﬂuorescent
tubes, kitchen objects, plates in a good contrast, bottles, cup han-
dle, washbasin, and bottles on shelves.
Fig. 4. Recognition tasks. Recognition tasks: (A) clock task, (B) reading letters, (C)
recognition of grey levels (for setup see Sections 2.4.3.3–2.4.3.5). The bars depict
percentages of patients who passed successfully the particular AFC tasks with the
implant power switched on (black bars) and off (grey bars) in all study visits (for
details see Sections 3.1.1.3–3.1.1.5). ⁄Above the bars indicate statistical signiﬁcance
(p < 0.05) if compared on vs. off in a non-parametric (Wilcoxon) test. ‘‘n’’ describes
the number of subjects who performed the particular test in the visits.
Fig. 5. Daily life experiences. Numbers of participants grouped according to their
reports of visual experiences in daily life. Eight participants did not beneﬁt from the
visual implant in daily life. Further eight participants could only localize objects. 13
participants reported regained visual experiences with descriptions of shapes or
details in scales of grey. For details of the descriptions see Section 3.1.2.
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3.2.1. Basic visual functions
Of 29 participants, four could not perceive any light using the
subretinal implant. The most probable reasons in these cases were:
(1) intraoperative touch of the optic nerve during device insertion,
with subsequent optic disc swelling interrupting MPDA signal
propagation by the ganglion cells; (2) retinal edema after implant
repositioning; (3) suspected retinal perfusion problems overlying
the MPDA; and (4) technical failure of the implant. The remaining
25 participants (86%) were able to perceive light via the subretinal
implant tested in a 2 alternative forced choice mode.
Using the non-parametric (Wilcoxon) test the performance over
all subjects was signiﬁcantly better (p < 0.05) with implant on vs.
off for light perception in all visits and for light localization in
months 1, 2, 3 and 6 (Fig. 6A–C).The highest speed for which the direction was correctly recog-
nized with the implant switched on ranged from 3 to 35 degrees
per second (Table 1). With the implant power off, one patient
passed the motion task (3.3 degrees per second) in a 4-AFC task
once by reaching 62.5% correct responses (Fig. 6C), but volunteered
that this was by guessing.
3.2.2. Spatial resolution
Using the non-parametric (Wilcoxon) test the performance over
all subjects was signiﬁcantly better (p < 0.05) with implant on vs.
off for the grating acuity in months 1, 2 and 3 (Fig. 7).
The grating acuity resolutions with implant power on ranged
from 0.1 to 3.3 cycles per degree (Table 1). Five participants passed
a 2 alternative forced choice grating acuity task once by reaching
75% correct responses despite chip power being switched off; four
of them indicated that it was done by guessing (Fig. 7A), whereas in
all ﬁve patients the grating acuity with implant power switched off
was lower than with the implant power on. Four participants suc-
cessfully completed standardized visual acuity (VA) testing using
contrast reversal Landolt C-rings, with VAs of 20/2000, 20/2000,
20/606 and 20/546 (Table 1).
3.3. Safety
Two serious adverse events (SAEs) were reported during the
trial: an increase of intraocular pressure up to 46 mmHg that
was successfully treated and resolved without sequelae; and reti-
nal detachment immediately after explantation of the device, trea-
ted surgically with laser coagulation and silicone oil, which
resolved but with local retinal ﬁbrotic changes.
Safety analyzes of the ﬁrst, monocentric part of the trial (mod-
ule 1, see Section 1) have been published recently (Kitiratschky
et al., 2014). A detailed description of the whole cohort of the clin-
ical trial safety data, including the non-serious adverse events
(AEs) will be presented in another publication. The adverse events
Fig. 6. Basic visual functions (‘‘screen tasks’’). Basic visual functions as assessed by
the BaLM test: (A) light perception, (B) light localization, (C) movement detections
(for setup see Section 2.4.1). The bars depict percentages of patients who passed
successfully the particular AFC tasks with the implant power switched on (black
bars) and off (grey bars) in all study visits (for details see Section 3.2.1). ⁄Above the
bars indicate statistical signiﬁcance (p < 0.05) if compared on vs. off in a non-
parametric (Wilcoxon) test. ‘‘n’’ describes the number of subjects who performed
the particular test in the visits.
Fig. 7. Spatial resolution. Measures of spatial resolution: (A) grating acuity, (B)
visual acuity measured with Landoldt C-rings (for setup see Section 2.4.2). The bars
depict percentages of patients who passed successfully the particular AFC tasks
with the implant power switched on (black bars) and off (grey bars) in all study
visits (for details see Section 3.2.2). ⁄Above the bars indicate statistical signiﬁcance
(p < 0.05) if compared on vs. off in a non-parametric (Wilcoxon) test. ‘‘n’’ describes
the number of subjects who performed the particular test in the visits.
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cause persistent or signiﬁcant health impairments. Two serious
adverse events occuring during module 1 phase could be treated
(Kitiratschky et al., 2014).
4. Discussion
These results provide proof of principle that a subretinal
implant can restore reliably measurable visual function and poten-
tially useful vision in low-vision or very low-vision range in
selected patients with end-stage degenerations of the outer retina
such as RP.
Vision with a subretinal implant differs from natural vision in a
healthy eye in several ways. Firstly, there is limited spatial resolu-
tion. The distance between the light-sensitive photodiodes is
70 lm in a square-shaped-array, allowing for a theoreticalmaximum VA of approximately 20/250. Preclinical work (Stett
et al., 2000) indicates that a distance of less than 50 lm between
the single planar electrodes does not improve spatial resolution
without additional measures, due to the dissipation of electrical
currents within the retinal tissue. Grating acuity and VA results
from some of our participants show that the measured VA comes
close to this theoretical limit; one participant achieved a grating
acuity of 3.3 cycles per degree, corresponding to 20/200.
Optotype and grating acuity, however, should not be directly com-
pared (Katz & Sireteanu, 1989), because grating acuity relies on
cues derived from angles of lines across a large visual ﬁeld (even
when lines are interrupted), whereas optotype VA depends on
the recognition of single optotype features in a very small visual
ﬁeld. The best Landolt C-rings acuity of the same participant was
20/546.
Secondly, electronic implants with planar electrodes do not
replicate normal color perception. The images perceived with the
subretinal implant are composed of grey levels, as the photodiodes
transform the luminance information into an electrical current
that, for each electrode, stimulates all color coding bipolar cell
types beneath the electrode. Most of the patients are able to distin-
guish several levels of grey. With a subretinal implant stimulating
an end-stage degenerated retina, the 70 lm  70 lm pixels cover
approximately 16 bipolar cells (Stingl et al., 2013c), a number that
also depends on the degree of retinal degeneration, with approxi-
mately 80% of bipolar cells still present after many years of blind-
ness (Santos et al., 1997). To date, it is not possible to stimulate the
cellular connections established earlier in life for green, red and
blue selectively and thereby restore natural color vision.
Thirdly, the visual ﬁeld is limited to the area of the photodiode
array. The square of the submacular implant measures
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to 15 of visual angle diagonally. This is sufﬁcient for orientation,
given that RP patients can quite well navigate with ﬁelds of this
size, but it still far more constricted than a normal visual ﬁeld.
Fourthly, contrast perception and brightness must be adjusted
manually in response to ambient illumination and patient prefer-
ence. On the hand-held battery unit, there are two knobs for man-
ual adjustment of both parameters. With visual training, patients
learn to adjust the transmission characteristics of the implant dur-
ing the ﬁrst days or weeks after implantation. The procedure is
reminiscent of optimizing the image in older black-and-white tele-
vision sets with two separate knobs for brightness and contrast.
The working range of the implant is relatively broad, with lumi-
nance from 1 to 100,000 cd/m2.
Lastly, the perceived image has a blinking character based on
the working frequency of the implant. Typically, this is set to
5 Hz, leading to a relatively constant image, but several partici-
pants preferred a lower frequency in order to prevent image fading,
other reached 20 Hz repetition rate. The origin of these differences
in temporal resolution without fading is not clear; there are indica-
tions that the ability to use the involuntary microsaccades that
allow refreshing the images may play a role and that utilization
of such microsaccades may improve over time or that an intrinsic
characteristic of the degenerated retina leads to different temporal
resolution capability.
Interestingly, the time necessary for re-learning vision is rela-
tively short. Localization of dots and direction of lines was possible
usually from the ﬁrst days, improving within days to weeks to the
best possible vision of the particular individual. An evidence for
this authors’ observation can be taken from the ﬁgures Figs. 3, 4,
6 and 7, showing that the results from the ‘‘month 1’’ visit are com-
parable to visit ‘‘month 2’’, followed by a slight decrease of the
functional results from the third month on (caused by technical
difﬁculties as described below).
Activities of daily living as well as real-life visual experiences
show that this type of subretinal multi-photodiode array can stim-
ulate the inner retina to obtain a useful perception. The increase in
visual function from blindness to a low-vision or very-low vision
range can provide signiﬁcant help for participants who became
blind from a chronically progressive degeneration of the retina.
The majority of the participants could at least localize objects with
a good contrast within their own environments. Almost half of the
participants gained useful visual experiences by being able to rec-
ognize the details of objects or shapes in real life. The ADL labora-
tory tests were performed with high contrast (white objects on a
black table) and showed a signiﬁcant improvement of the detec-
tion, localization, and identiﬁcation of objects in the near-vision
range, compared to the results with the implant off during the ﬁrst
three months.
The improved vision seen in some participants after several
months with the implant power being switched off might possibly
be explained by the well-known release of growth factors that
occurs after electrical stimulation. Both pre-clinical (Morimoto
et al., 2012; Schmid et al., 2009) and clinical studies (Schatz
et al., 2011) suggest that this can in turn improve visual function.
Indeed, a few participants spontaneously reported an improved
light perception with the implant off, especially at the end of the
study. Such observations of improvement of remaining vision have
been made also in previous attempts to restore vision by subretinal
implants in RP patients (Chow et al., 2004). Although those
implants – due to very peripheral position and lack of electronic
ampliﬁcation – did not provide vision restoration, central vision
in such patients improved considerably, probably due to effects
of growth factors (Pardue et al., 2005). We assume that the func-
tional improvements seen in our patients during the course of
the study also with non-activated implants may be due to suchwell established treatment effects after continued electrical stimu-
lation in patients that had still light perception preoperatively.
Additionally, in almost all tests a decrease of function over time
with the implant power switched on was observed in a number of
participants (Figs. 3, 4, 6 and 7). There are no indications that this
phenomenon is caused by biological reasons such as retinal struc-
ture changes or local adverse events. Rather, the decrease of the
functional performance after implantation was caused by technical
failures of the implants occurring in some cases already after
3–12 months after implantation, which is also one of the reasons
why the number of participants performing the tests in the later
visits decreases. In some patients breaks in the intraorbital cable
part caused by the mechanical stress from eye movements
occurred (Kernstock et al., 2011). This problem has meanwhile
been successfully solved by a surgical technique leading the
intraorbital part of the cable in a parabulbar loop minimizing the
mechanical stress onto the cable during eye movements, so that
this problem did not occur beyond the seventh participant of the
trial. Other modes of technical failures have been solved by
improving encapsulation of the electronic chip which in laboratory
tests showed a considerably prolonged lifetime, currently assessed
also in the ongoing clinical trial.
The reaction time was limited to 4 min in the ADL tasks and to
2 min in the recognition tasks. In the screen tasks there were
mostly no timeout as usually the responses took several seconds
only; however, some participants wanted the pattern presented
up to several minutes. The authors learned that this measure is
more an expression of the patient’s personality than a functionality
parameter; some patients report their ﬁrst impression immedi-
ately, whereas many patients try check more times or have difﬁ-
culties to make a decision in an AFC test, prolonging thus the
reaction time although they commented afterwards that their ﬁrst
impression did not change much.
As we published previously, the best visual function is obtained
if the chip is located in a subfoveal position (Stingl et al., 2013c;
Zrenner et al., 2011). Before surgery, the desired subfoveal position
is determined (Kusnyerik et al., 2012). However, due to adhesions,
foveal thinning, the curvature of the eye, and the length and ﬂexi-
bility of the polyimide foil, it is not always possible to precisely
position the chip. Among the 29 participants, the foveola was on
the MPDA in 11 cases, on the chip but close to the MPDA border
in 12 cases, and not on the MPDA in 6 cases (usually with a paraf-
oveal position, but up to 3.8 mm away from the nearest chip bor-
der). An evaluation of best achieved functional measures for each
individual shows also in this cohort, that a parafoveal position
most likely limits the best possible spatial resolution (Fig. 6); grat-
ing acuity and visual acuity with Landolt C-rings are achievable in
more participants and of higher value if the fovea is on the micro-
chip surface (Fig. 8A and B). However, the fovea placement in rela-
tion to the microchip does not seem to play a big role for most daily
life experiences or the number of distinguishable grey scales
(Fig. 8C and D). This might be explained by the low level of vision
(low-vision or very-low-vision) that the implant can restore, which
is biologically achievable in the whole macular region. Also the
amount of distinguishable grey levels is not a direct capability of
the fovea alone.
We do not see any direct effect of age or disease duration on the
functional outcome. However, the authors have an impression that
a kind of ability and motivation to learn a ‘‘new perception’’ and
understand the principal function and technical possibilities of
the implant might be advantageous, but this is not a measure
which could be objectively documented.
Worldwide, currently subretinal, epiretinal, suprachoroidal,
cortical and optic nerve implant are under development (Brelén
et al., 2010; Humayun et al., 2012; Schmidt et al., 1996; Weiland,
Cho, & Humayun, 2011; Zrenner, 2002, 2012, 2013). At present,
Fig. 8. Effect of the position of the fovea to the subretinal microchip. The color-coded dots represent participants, for whom the results of grating acuity (A), visual acuity (B),
daily life reports (C) and number of correctly documented grey scales (D) were available. The colors of the dots represent where the fovea was placed in relation on to the
microchip in the particular participant: para (chip was parafoveally, thus the fovea was not on the chip surface), corner (fovea was in the region of the chip corner), margin
(fovea was close to the chip border) and centre (fovea was on the microchip surface, not in the proximity of the border). (A) Grating acuity and (B) visual acuity with Landolt
C-rings were better and more often measureable if the fovea was stimulated by the chip (chip not parafoveally). (C) Daily life experiences and (D) number of distinguishable
grey levels do not show such a tendency.
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Sylmar USA) prosthesis with the FDA approval and the subretinal
Alpha IMS (Retina Implant AG, Reutlingen Germany) implant, both
having received the CE mark for use in Europe, have been the sub-
jects of long-term clinical studies in blind patients with hereditary
retinal degenerations. Recently also a small number of patients
with a suprachoroidal implant have been reported (Ayton et al.,
2014). Moreover, there are earlier reports on human patients with
a passive subretinal implant (Chow et al., 2010) and EPIRET3,
another epiretinal prosthesis (Menzel-Severing et al., 2012) who
did not report on daily life experiences, mediated regularly by elec-
tronic implant devices.
Both subretinal implant Alpha IMS and the epiretinal implant
Argus II could show improvement of the vision in end-stage retini-
tis pigmentosa patients. However, there are several differences in
both systems. The epiretinal prosthesis uses an external camera
afﬁxed to spectacles and stimulates directly the ganglion cells with
a transformed signal via 60 electrodes, and thus does not primarily
involve the bipolar and amacrine cells. This might be an advantage
in cases where the bipolar cells layer has degenerated profoundly
and ganglion cell system being intact which is rarely the case; to
our opinion, including the bipolar cell and amacrine cell circuitry
in the visual processing is an enormous advantage for a more nat-
ural perception and fast restoration. Inner retina circuitry carries
out a number of important processes such as contrast enhance-
ment or movement perception and enable – in contrary to the long
ganglion cells axons – a good retinotopy of the image. Moreover,
histological work show that the bipolar cell layer usually – despite
some reorganization – is present in most patients after years of
blindness (Santos et al., 1997) and does not degenerate profoundly
even in end-stage disease. Further, the use of an external camera
eliminates the chance of utilizing natural eye movements which
are important not only for visual search but also serve to prevent
image fading on the retina by small involuntary eye movements
that refresh images during visual perception and maintain imageposition stability by the efference copy transmission to the brain,
for which the utilization of the extraocular muscle system is
instrumental.
Indeed, patients with Subretinal Implant Alpha IMS move their
eyes in order to ﬁnd and localize the objects. In the screen tasks,
once they have found the object on the area of the microchip, most
patients can see the spatial characteristics and shape without using
gaze or head movements. For outdoor use or during scanning lar-
ger areas such as table, head movements are necessary, too.
Patients wearing a subretinal implant also perform microsaccades
with their eyes, refreshing thus the image on the retina (Hafed
et al., publication in progress).
Nevertheless an external camera and image pre-processing as
necessary for the epiretinal approach brings additional advantages.
Accommodation and magniﬁcation by zooming in the camera sys-
tem can improve perception of details (Humayun et al., 2012) and
preprocessing of images might enable some additional encoding of
information, although such technical measures cannot improve
visual acuity, as assessed in proper ophthalmological terms.
Moreover, optical magnifying devices for low vision such as lenses
can be applied with subretinal implants as well.
Another advantage of the epiretinal approach is an easier surgi-
cal insertion – the median implant surgery time is 4 h (Humayun
et al., 2012) compared to six to eight hours in the case of the sub-
retinal implantation. The epiretinal system has also shown longer
observation times the follow-up of patients wearing the epiretinal
prosthesis reaches up to 2.7 years (Humayun et al., 2012) and
meanwhile longer (>5 years).
On the other hand, the Alpha IMS with 1500 electrodes has
shown better visual results so far, compared to the Argus II with
60 electrodes. The best result of grating visual acuity mediated
by Argus II to date is 20/1262 (Humayun et al., 2012) (decimal
0.016), visual acuity measured by standardized Landolt C-ring tests
with an epiretinal prosthesis was not reported so far. Also the
range of daily life reports of patients wearing Alpha IMS is broader
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several fold, presently assessed in clinical trials.
Microelectronic visual implants are designed for completely
blind persons with retinal degenerations. However, especially for
low vision and very low vision patients a number of non-invasive
visual rehabilitation tools have been developed to allow for an
improved functional performance and visual rehabilitation.
Optical and electronic magnifying devices are available on the mar-
ket for many years, enabling a regular or contrast-reversal magni-
ﬁcation of up to 70-times. Mobile digital devices based on video
goggles can zoom, autofocus, and adapt to ambient luminance in
an enlarged visual ﬁeld, but most of the devices have a bulky
appearance which is socially not easily acceptable. An alternative
approach is the tongue stimulator, a non-invasive device which
transfers the visual image into a vibrating pattern on the tongue.
With the tongue stimulator ‘‘Brainport’’ blind individuals can pass
the light perception, time resolution and grating acuity task in a
screen module similar to the setup described in the present manu-
script (Nau, Bach, & Fisher, 2013). Also conversion of the image into
acoustical signals is used for orientation and mobility, letter recog-
nition and other visual tasks, as was published for congenitally
blind individuals (Striem-Amit et al., 2012). For recent advances
see also The Lasker/IRRF Initiative for Innovation in Vision
Science, (2014b, chap. 9).5. Conclusions
The results of our study show that a subretinal implant is able
to restore rudimentary but potentially useful vision in patients
blind from hereditary degenerations of the photoreceptors.
Almost half of the participants could recognize object shapes and
detail in daily life and almost three-quarters could localize
high-contrast objects. The implant received a CE mark granting
marketing authorization within the European Community in July
2013 and for some centers in Germany public health insurance
negotiations for reimbursement have been positive. Nevertheless
it is of utmost importance that interested patients are properly
informed about the present limitations of electronic implants and
that the maximum achievable visual restoration is corresponding
only to very low vision of a kind that patients may have experi-
enced just before becoming blind. Moreover, despite well main-
tained retinal layering, assessed by OCT, it cannot be predicted at
present, which patients after implantation may have very useful
object perception in daily life and which patients may have only
improved light perception and how long the restoration of
very-low-vision abilities will be maintained.Conﬂicts of interest
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